benefits of glp 1 agonists Cardiovascular glucagon-like peptide-1 receptor Glucagon-like peptide 1 receptor agonists:

This figure is remarkable in the context of GLP-1 therapeutics: oral semaglutide (Rybelsus), despite incorporating the SNAC absorption enhancer, achieves oral bioavailability of only 0.4-1.0%, meaning that more than 99% of the ingested semaglutide peptide is lost to gastrointestinal degradation and poor absorption

According to Sequoias 2025 Wellbeing Trends report, 26% of employers cover GLP-1 medications, with an additional 20% planning to add coverage in the next year

You can change that thats wild

Patel K, Harrison SA, Elkhashab M et al (2020) Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Once bound to GLP-1R, GLP-1 initiates a cascade of events, including the activation of membrane-bound adenylyl cyclase (AC) leading to cyclic adenosine monophosphate (cAMP) synthesis

This availability difference may influence your decision if needle anxiety or injection site issues have become problematic